CN102389595B - Non-drug treatment system for inactivation of HIV (human immunodeficiency virus) and other viruses - Google Patents
Non-drug treatment system for inactivation of HIV (human immunodeficiency virus) and other viruses Download PDFInfo
- Publication number
- CN102389595B CN102389595B CN201110197182.2A CN201110197182A CN102389595B CN 102389595 B CN102389595 B CN 102389595B CN 201110197182 A CN201110197182 A CN 201110197182A CN 102389595 B CN102389595 B CN 102389595B
- Authority
- CN
- China
- Prior art keywords
- plasma
- blood
- inactivation
- virus
- treatment bag
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Abstract
The invention relates to a treatment system for carrying out autologous plasma virus inactivation for non-drug antivirus treatment on patients infected by lipid-enveloped viruses including HIV (human immunodeficiency virus) and the like caused by drug-resistant strains and variant strains. The treatment system comprises a plasma collector, a disposable separation and virus inactivation multi-purpose processor for collected plasma, an MB virus inactivator and an HHP virus inactivator, wherein the disposable separation and virus inactivation multi-purpose processor for collected plasma comprises a blood collector, a pipeline, a plasma separation cup, a lengthened plasma pipeline, a photochemical processing bag for pancake plasma collection and inactivation, a processing bag for tubular plasma collection and extra-high-pressure virus inactivation, an MB self-medicating pot, a puncture cap, a retaining clip, a blood filter, a pressure monitor, a saline water reinfusion needle and protection cap thereof, and an anticoagulant and protection cap thereof. The invention has the advantages of wide application range, good virus inactivation effect, wide spectrum of inactivated viruses, convenient operation process, high safety and efficiency and low cost, thereby being suitable to be popularized.
Description
Technical field
This is the inactivation of virus therapy system such as a kind of non-medicine HIV for the present invention, belongs to infectious disease treatment, safe transfusion, blood products field.
Background technology
The Chinese full name of acquired immune deficiency syndrome (AIDS) (AIDS): acquired immune deficiency syndrome (AIDS).It is by HIV (human immunodeficiency virus) (HIV), to be infected the new viral infectious of a kind of highly infective causing.Decades, harm was known by the whole world to human catastrophe, and from 1981, various countries dropped into huge financial resources, material resources, science and technology and social resources developing drugs so far, developed vaccine.But because HIV (human immunodeficiency virus) has quite a lot of still lost own characteristic, in time range, do not find yet and can cure this sick ideal medicament and method completely so far, there is no the effectively vaccine of prevention yet.End 2010, China's accumulative total is reported HIV/AIDS37 ten thousand many cases, wherein dead 6.8 ten thousand examples.Ministry of Public Health is announced the infection total number of persons 740,000 of estimating." cocktail " strengthening antiviral therapy is the Therapeutic Method of extensive use in current world wide, and along with the prolongation for the treatment of time, the patient who receives treatment shows increasing practical problem.Especially, the toxic and side effects that medicine is serious, the drug resistance that virus very easily produces and virus variation and immune evasion, high medical expense, all feels patient and society and is difficult to bear in addition.The situation of Prevention & Control of AIDS is still severe, and new drug development and vaccine development all lag behind realities of the day far away.Global range all expects that new Therapeutic Method and means, especially developing country will be placed on traditional medicine attention and excavate single medicine and some other cheap effectively Therapeutic Method in a hurry.China's HIV/AIDS prevention also proposes " will strengthen scientific research and on the basis of existing antiviral therapy, in conjunction with national conditions, accelerate the applied research of prophylactico-therapeutic measures, wide receipts won, and uses by oneself ".This worldwide new special health problem of reply acquired immune deficiency syndrome (AIDS), treatment approaches and methods that must be new with the Thinking Exploration of innovating completely.
Summary of the invention
The invention provides the inactivation of virus therapy system such as a kind of non-medicine HIV, adopting this system to carry out self-plasma virus deactivation treatment to lipid-coated virus infected patients such as HIV, HBV, HCV processes, directly cause the viruses such as HIV to be inactivated and reach the object for the treatment of, the present invention is with low cost, safe and effective, antiviral spectrum is wide, simple in structure, easy to operate, good with existing equipment compatibility, suitable popularization.
The technical solution used in the present invention is: the inactivation of virus therapy system such as non-medicine HIV, comprise: blood plasma collecting machine, disposable machine-collected plasma isolated viral deactivation Multi-purpose processor, MB virus inactivation instrument, HHP virus inactivation instrument, wherein disposable machine-collected plasma isolated viral deactivation Multi-purpose processor comprises: hemostix, pipeline, separating plasma cup, tubular plasma collection supertension inactivation treatment bag, lengthen blood plasma pipeline, pie plasma collection deactivation photochemical treatment bag, MB is from dosing fort, puncture cap, flow-stopping clip, blood filter, pressure monitor, saline feeds back pin and helmet, anticoagulant and helmet, it is characterized in that hemostix arranges connecting tee after flow-stopping clip, feed back pin and helmet and anticoagulant and helmet with saline again the pipeline of flow-stopping clip after in parallel is set, blood filter connects, blood filter Bonding pressure monitor, and be connected with separating plasma cup by pipeline, separating plasma cup is by lengthening after blood plasma pipeline connecting tee and tubular plasma collection supertension inactivation treatment bag, pie plasma collection deactivation photochemical treatment bag connects, wherein the preposition flow-stopping clip of tubular plasma collection supertension inactivation treatment bag is connected with the threeway that lengthening blood plasma pipeline is connected, pie plasma collection deactivation photochemical treatment bag is by two threeways, add respectively flow-stopping clip, flow-stopping clip is connected with the threeway that lengthening blood plasma pipeline is connected from dosing fort with MB, on tubular plasma collection supertension inactivation treatment bag and pie plasma collection deactivation photochemical treatment bag, puncture cap is set respectively.
The application of the inactivation of virus therapy system such as non-medicine HIV of the present invention, when blood is by hemostix flow ipe from human body collection, injects anticoagulant by anticoagulant and helmet, now saline feeds back pin and helmet closedown of pipeline, the blood that injects anticoagulant flows into separating plasma cup by blood filter, before closing the tubular plasma collection supertension preposition pipeline of viral inactivation treatment bag and pie plasma collection deactivation photochemical treatment bag, MB is not set from a segment pipe in dosing fort, the blood plasma flowing out by separating plasma cup enters pie plasma collection deactivation photochemical treatment bag by being provided with the passage of MB from dosing fort, pie plasma collection deactivation photochemical treatment bag front end arranges MB from dosing fort, the inside adds MB, wherein MB belongs to phenothiazines dyestuff, it is a kind of light-sensitive coloring agent, can efficient inactivation lipid-containing envelope virus, comprise retrovirus, herpesvirus, togavirus, yellow fever virus etc., plasma collection in pie plasma collection deactivation photochemical treatment bag is after specified amount, close the preposition flow-stopping clip of pie plasma collection deactivation photochemical treatment bag, pie plasma collection deactivation photochemical treatment bag is put into MB blood-plasma virus killing instrument and is carried out deactivation, the ball of blood plasma collecting machine auto back blood transfusion simultaneously, when blood cell feeds back residue 5-10ml, suspend feedback program, after deactivation completes, unclamp the preposition flow-stopping clip of pie plasma collection deactivation photochemical treatment bag, allow the blood plasma after deactivation in pie plasma collection deactivation photochemical treatment bag feed back program by opening blood plasma collecting machine, carry out human body feedback, the course for the treatment of, number of times can carry out repeatedly blood-plasma virus killing according to patient's situation, reach therapeutic purposes.
When blood is by hemostix flow ipe from human body collection, by anticoagulant and helmet, inject anticoagulant, now saline feeds back pin and helmet closedown of pipeline, the blood that injects anticoagulant flows into separating plasma cup by blood filter, close the preposition flow-stopping clip of pie plasma collection deactivation photochemical treatment bag, the blood plasma flowing out by separating plasma cup enters tubular plasma collection supertension inactivation treatment bag, capacity can be at 200ml-800ml, blood plasma flows into tubular plasma collection supertension inactivation treatment bag by pipeline, blood plasma collecting machine auto back blood transfusion ball after reaching quantitative blood plasma, then cutting out pipeline is carried out and is fused, tubular plasma collection supertension inactivation treatment bag is put into HHP blood-plasma virus killing instrument and carry out inactivation of virus, blood plasma is at 5 ℃～15 ℃, under 250～350MPa condition after pressurized treatments 5-10 minute, pressure release is made zero, pressurization pressure release circulation 1-3 time, blood plasma in tubular plasma collection supertension inactivation treatment bag is after the deactivation of HHP blood-plasma virus killing instrument, close anticoagulant pipeline, blood plasma after deactivation can feed back pin by saline and feed back patient, also can feed back human body through other liquid roads, reach therapeutic purposes.Make may exist in blood plasma the lipid-containing envelope viruses such as HIV, HBV, HCV that comprise persister and variant to be inactivated, reach the therapeutic purposes that alleviate virus loads and protection CD4 immunocyte and immunologic reconstitution in blood circulation.Meanwhile, this therapy system also has effective deactivation to nonenveloped viruses such as EMCV.
The present invention has obtained following beneficial effect: adopt the inactivation of virus therapy system such as non-medicine HIV, the processor that the blood plasma collecting machine of prior art and blood-plasma virus killing apparatus can be set up with inventor and the combination of fitting operation program chains realize separating plasma MB Automatic Dosing, MB inactivation of virus and HHP supertension inactivation of virus, after deactivation, blood plasma feeds back and carries out respectively totally enclosed type or be interrupted closed processing.Patient HIV/AIDS is treated, can make HIV virus structure in patient's blood plasma and function directly be destroyed inactivation and effectively alleviate at short notice the HIV (human immunodeficiency virus) load in patient's blood circulation.Virus is lost and infect and the active ability copying, reach the object of antiviral and immunization therapy.This therapy is applicable to each period, particularly early treatment of HIV (human immunodeficiency virus) infection, there is no toxic and side effects, does not produce persister, effective equally to variant, and technology maturation, and expense is cheap, suitable popularization.
Accompanying drawing explanation
Fig. 1 is the inactivation of virus therapy system structural representations such as non-medicine HIV, wherein.
1-hemostix, 2-pipeline, 3-separating plasma cup, 4-tubular plasma collection supertension inactivation treatment bag, 5-lengthens blood plasma pipeline, 6-pie plasma collection deactivation photochemical treatment bag, and 7-MB is from dosing fort, the 8-cap that punctures, 9-flow-stopping clip, 10-blood filter, 11-pressure monitor, 12-saline feeds back pin and helmet, 13-anticoagulant and helmet.
The specific embodiment
Below in conjunction with accompanying drawing, the present invention is done to a detailed description:
Embodiment 1: when blood is by hemostix flow ipe from human body collection, by anticoagulant and helmet, inject anticoagulant, now saline feeds back pin and helmet closedown of pipeline, the blood that injects anticoagulant flows into separating plasma cup by blood filter, before closing the tubular plasma collection supertension preposition pipeline of viral inactivation treatment bag and pie plasma collection deactivation photochemical treatment bag, MB is not set from a segment pipe in dosing fort, the blood plasma flowing out by separating plasma cup enters pie plasma collection deactivation photochemical treatment bag by being provided with the passage of MB from dosing fort, pie plasma collection deactivation photochemical treatment bag front end arranges MB from dosing fort, the inside adds MB, wherein MB belongs to phenothiazines dyestuff, it is a kind of light-sensitive coloring agent, can efficient inactivation lipid-containing envelope virus, comprise HIV, HBV, the lipid-coated virus such as HCV and herpesvirus, togavirus, yellow fever virus etc.Blood plasma in pie plasma collection deactivation photochemical treatment bag is input to after specified amount, plasma collection in pie plasma collection deactivation photochemical treatment bag is after specified amount, close the preposition flow-stopping clip of pie plasma collection deactivation photochemical treatment bag, pie plasma collection deactivation photochemical treatment bag is put into MB blood-plasma virus killing instrument and is carried out deactivation, the ball of blood plasma collecting machine auto back blood transfusion simultaneously, when blood cell feeds back residue 5-10ml, suspend feedback program, after deactivation completes, unclamp the preposition flow-stopping clip of pie plasma collection deactivation photochemical treatment bag, allow the blood plasma after deactivation in pie plasma collection deactivation photochemical treatment bag feed back program by opening blood plasma collecting machine, carry out human body feedback, the course for the treatment of, number of times can carry out repeatedly blood-plasma virus killing according to patient's situation, reach therapeutic purposes.
Embodiment 2: when blood is by hemostix flow ipe from human body collection, by anticoagulant and helmet, inject anticoagulant, now saline feeds back pin and helmet closedown of pipeline, the blood that injects anticoagulant flows into separating plasma cup by blood filter, close the preposition flow-stopping clip of pie plasma collection deactivation photochemical treatment bag, the blood plasma flowing out by separating plasma cup enters tubular plasma collection supertension inactivation treatment bag, capacity can be at 200ml-800ml, blood plasma flows into tubular plasma collection supertension inactivation treatment bag by pipeline, blood plasma collecting machine auto back blood transfusion ball after reaching quantitative blood plasma, then cutting out pipeline is carried out and is fused, tubular plasma collection supertension inactivation treatment bag is put into HHP blood-plasma virus killing instrument and carry out inactivation of virus, blood plasma is at 5 ℃～15 ℃, under 250～350MPa condition after pressurized treatments 5-10 minute, pressure release is made zero, pressurization pressure release circulation 1-3 time, blood plasma in tubular plasma collection supertension inactivation treatment bag is after the deactivation of HHP blood-plasma virus killing instrument, close anticoagulant pipeline, blood plasma after deactivation can feed back pin by saline and feed back patient, also can feed back human body through other liquid roads, reach therapeutic purposes.Make may exist in blood plasma the lipid-containing envelope viruses such as HIV, HBV, HCV that comprise persister and variant to be inactivated, reach the therapeutic purposes that alleviate virus loads and protection CD4 immunocyte and immunologic reconstitution in blood circulation.Meanwhile, this therapy system also has effective deactivation to nonenveloped viruses such as EMCV.
Embodiment 3: can also can be combined with by carrying out deactivation in the instrument deactivation of HHP blood-plasma virus killing and MB blood-plasma virus killing instrument, carry out dual inactivation of virus.
The present invention also has deactivation to nonenveloped virus except the lipid-coated virus such as HIV.As reduced and be greater than 7.0log, TCID after EMCV, 300MPa, 3Min deactivation.Therefore the opportunistic infection due to born of the same parents' gizzard virus etc. is infected are the effective therapeutical effect of tool also.
Claims (3)
1. non-medicine HIV inactivation of virus therapy system, comprise: blood plasma collecting machine, disposable machine-collected plasma isolated viral deactivation Multi-purpose processor, MB virus inactivation instrument, HHP virus inactivation instrument, wherein disposable machine-collected plasma isolated viral deactivation Multi-purpose processor comprises: hemostix, pipeline, separating plasma cup, tubular plasma collection supertension inactivation treatment bag, lengthen blood plasma pipeline, pie plasma collection deactivation photochemical treatment bag, MB is from dosing fort, puncture cap, flow-stopping clip, blood filter, pressure monitor, saline feeds back pin and helmet, anticoagulant and helmet, it is characterized in that hemostix arranges connecting tee after flow-stopping clip, feed back pin and helmet and anticoagulant and helmet with saline again the pipeline of flow-stopping clip after in parallel is set, blood filter connects, blood filter Bonding pressure monitor, and be connected with separating plasma cup by pipeline, separating plasma cup is by lengthening after blood plasma pipeline connecting tee and tubular plasma collection supertension inactivation treatment bag, pie plasma collection deactivation photochemical treatment bag connects, wherein the preposition flow-stopping clip of tubular plasma collection supertension inactivation treatment bag is connected with the threeway that lengthening blood plasma pipeline is connected, pie plasma collection deactivation photochemical treatment bag is by two threeways, add respectively flow-stopping clip, flow-stopping clip is connected with the threeway that lengthening blood plasma pipeline is connected from dosing fort with MB, on tubular plasma collection supertension inactivation treatment bag and pie plasma collection deactivation photochemical treatment bag, puncture cap is set respectively.
2. non-medicine HIV inactivation of virus therapy system according to claim 1, is characterized in that: blood, by hemostix flow ipe from human body collection, injects anticoagulant by anticoagulant and helmet, now saline feeds back pin and helmet closedown of pipeline, the blood that injects anticoagulant flows into separating plasma cup by blood filter, close the preposition flow-stopping clip of pie plasma collection deactivation photochemical treatment bag, the blood plasma flowing out by separating plasma cup enters tubular plasma collection supertension inactivation treatment bag, capacity is at 200ml-800ml, blood plasma flows into tubular plasma collection supertension inactivation treatment bag by pipeline, blood plasma collecting machine auto back blood transfusion ball after reaching quantitative blood plasma, then cutting out pipeline is carried out and is fused, tubular plasma collection supertension inactivation treatment bag is put into HHP blood-plasma virus killing instrument and carry out inactivation of virus, blood plasma in tubular plasma collection supertension inactivation treatment bag is after the deactivation of HHP blood-plasma virus killing instrument, close anticoagulant pipeline, blood plasma after deactivation can feed back pin by saline and feed back patient, also through other liquid roads, feed back human body, reach therapeutic purposes.
3. non-medicine HIV inactivation of virus therapy system according to claim 1, is characterized in that: tubular plasma collection supertension inactivation treatment bag, pie plasma collection deactivation photochemical treatment bag are all above blood plasma collecting bags.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110197182.2A CN102389595B (en) | 2011-07-14 | 2011-07-14 | Non-drug treatment system for inactivation of HIV (human immunodeficiency virus) and other viruses |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110197182.2A CN102389595B (en) | 2011-07-14 | 2011-07-14 | Non-drug treatment system for inactivation of HIV (human immunodeficiency virus) and other viruses |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102389595A CN102389595A (en) | 2012-03-28 |
| CN102389595B true CN102389595B (en) | 2014-09-24 |
Family
ID=45857058
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201110197182.2A Active CN102389595B (en) | 2011-07-14 | 2011-07-14 | Non-drug treatment system for inactivation of HIV (human immunodeficiency virus) and other viruses |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102389595B (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104174042A (en) * | 2014-08-29 | 2014-12-03 | 郑州飞龙医疗设备有限公司 | Ultrahigh-pressure inactivating method for pathogens in biological products and applications thereof |
| CN104399135A (en) * | 2014-11-20 | 2015-03-11 | 上海市血液中心 | Processing device for plasma virus inactivation |
| CN107715211A (en) * | 2017-11-01 | 2018-02-23 | 杭州蕙新医疗科技有限公司 | A kind of plasma exchange loading photochemical virus inactivation device and its application apparatus |
| CN108498795A (en) * | 2018-03-22 | 2018-09-07 | 耿艳春 | The one-step preparation process of therapeutic type drug resistance AIDS self-plasma virus deactivation vaccine |
| CN112386717B (en) * | 2020-12-11 | 2022-05-24 | 西安市中心医院 | Disposable blood virus inactivation device |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE29801590U1 (en) * | 1998-01-30 | 1998-04-16 | Maco Pharma Int Gmbh | Blood bag system for virus inactivation of blood, blood components and plasma |
| DE19904088A1 (en) * | 1999-02-02 | 2000-09-07 | Fressenius Hemocare Gmbh | Tubing set for a cell separator for separating blood into its components and method for separating blood into its components |
| US6284142B1 (en) * | 1999-09-03 | 2001-09-04 | Baxter International Inc. | Sensing systems and methods for differentiating between different cellular blood species during extracorporeal blood separation or processing |
| CN2411003Y (en) * | 2000-03-30 | 2000-12-20 | 孙锦山 | Channel of dispersable mechanical blood sampling erythrocye and plasma separator |
| WO2006110470A1 (en) * | 2005-04-08 | 2006-10-19 | Mission Medical, Inc. | Centrifuge for blood processing systems |
| CN2827384Y (en) * | 2005-05-18 | 2006-10-18 | 李金城 | Disposable device for plasma-taking and virus-inactivation separator |
-
2011
- 2011-07-14 CN CN201110197182.2A patent/CN102389595B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN102389595A (en) | 2012-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102389595B (en) | Non-drug treatment system for inactivation of HIV (human immunodeficiency virus) and other viruses | |
| Periyavan et al. | Distribution of ABO and Rhesus-D blood groups in and around Bangalore | |
| Lelie et al. | Inactivation of 12 viruses by heating steps applied during manufacture of a hepatitis B vaccine | |
| WO1987006119A1 (en) | Anti-pathogenic blood collection system and method | |
| CN201020070Y (en) | Full-automatic self-plasma virus deactivation therapeutic equipment | |
| Gisselquist et al. | Efficiency of Human Immunodeficiency Virus Transmission Through Injections and Other Medical Procedures Evidence, Estimates, and Unfinished Business | |
| CN202236530U (en) | Leucocyte removal blood bag capable of inactivating viruses | |
| CN2827384Y (en) | Disposable device for plasma-taking and virus-inactivation separator | |
| Skinner et al. | Overcoming the immune privilege of B cell follicles to cure HIV-1 infection | |
| US11197924B2 (en) | Photochemical preparation method for autologous plasma inactivated vaccine for treating AIDS | |
| CN201271255Y (en) | Blood bag with device for inactivating and filtering blood plasma virus | |
| CN2803274Y (en) | Disposable machine extrating and blood plasma virus deactivating hemostix | |
| CN215840804U (en) | Disposable machine blood sampling purifying treatment pipeline | |
| YOUNG | Prophylactic granulocytes in the neutropenic host | |
| CN101002949A (en) | HIV-Env gene DNA allosterism recombination envelope protein antigen for immunoresponsiveness of anti-HIV test and method | |
| CN108498795A (en) | The one-step preparation process of therapeutic type drug resistance AIDS self-plasma virus deactivation vaccine | |
| Kiene et al. | Hepatitis, HIV, and the dermatologist: a risk review | |
| Ala’a Hadi Alessami | Seroprevalence of Hepatitis B and C among Hemodialysis patients in Ad Diwaniyah governorate | |
| Yadav | Therapeutic Plasma Exchange for COVID-19 Patients | |
| Chukhno et al. | Difficulties of differential diagnosis of polyneuropathy developed after Gam-COVID-Vac vaccination on the background of combined infectious pathology (clinical case). | |
| CN207186875U (en) | The integrated medical treatment device of one kind administration blood sampling | |
| CN104815052A (en) | Chinese medicinal composition for resisting influenza virus infection and preparation method thereof | |
| CN105816323B (en) | A kind of immunocyte preparation feedback bag | |
| CN202236536U (en) | Multi-purpose processor for disposable machine collected blood plasma separation and viral inactivation | |
| CN102309790B (en) | Disposable safety transfusion apparatus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Non-drug treatment system for inactivation of HIV (human immunodeficiency virus) and other viruses Effective date of registration: 20160624 Granted publication date: 20140924 Pledgee: Henan SME Investment Guarantee Limited by Share Ltd Pledgor: Zhengzhou Feilong Medical Equipment Co., Ltd. Registration number: 2016990000495 |
|
| PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20170728 Granted publication date: 20140924 Pledgee: Henan SME Investment Guarantee Limited by Share Ltd Pledgor: Zhengzhou Feilong Medical Equipment Co., Ltd. Registration number: 2016990000495 |